QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)

Intuitive Surgical (NASDAQ:ISRG) Stock a Buy: Cutting-Edge Medical Tech

Wednesday, September 2, 2020 | Sean Sechler
Intuitive Surgical (NASDAQ:ISRG) Stock a Buy: Cutting-Edge Medical Tech

Did you know that healthcare spending makes up more than 10% of the GDP in most developed countries? In the United States, the spending is near twice that amount and accounted for 17.7% of GDP in 2018. With a global pandemic bringing the healthcare industry front and center, it’s easy to see the potential for companies that are innovating in the medical world. The huge amount of spending is only going to increase in the coming years, which is why investors might want to look at adding stocks in the healthcare industry going forward.

For example, Intuitive Surgical (NASDAQ:ISRG) is a company producing cutting-edge medical technology that is changing the way that surgeries are performed. Here are some reasons why this stock could be a great buy for long-term investors.

Benefits of Robotic Surgery

Intuitive Surgical is a MedTech company that has been a true pioneer in the robotic-assisted minimally invasive surgery field. Although it might seem strange to consider putting your life in the hands of robotics, this is likely going to be the norm for surgeries as the years go by. There are several reasons why robotic surgery is so groundbreaking. Patients can expect more accurate surgery, significantly less pain, lower risk of infection and blood loss, less scarring, shorter recovery, and better clinical outcomes for many cases. That’s why Intuitive Surgical is such a compelling company.  

The company’s cutting-edge da Vinci Surgical Systems allow surgeons to perform robotic-assisted minimally invasive surgeries with greater precision thanks to advanced robotics and computerized visualization technology. The system uses tiny wristed instruments that move like a human hand with a better range of motion along with highly magnified 3D high-definition views of the surgical area. Intuitive Surgical has already sold over 5,550 da Vinci robotic systems that have assisted with more than 7 million surgeries to date, and there’s a strong possibility that number increases substantially over the next decade.

The Next Big Thing in Medical Technology

One of the big reasons why Intuitive is worth a look for your portfolio is due to the massive growth prospects of medical technology over the next few years. We alluded to the huge healthcare spend that occurs worldwide earlier in this article, but the market for surgical robots specifically is expected to grow from $6.7 billion in 2020 to $11.8 billion by 2025. That’s a CAGR of 12.1% that could directly benefit Intuitive Surgical since it has already established competitive and technological dominance in the market.

Although there could be competitors in the future, investors should understand that there is a high cost of switching robotic surgery platforms. That means this company could have loyal customers for years to come. The da Vinci systems are certainly not cheap, with the average selling price excluding operating leases and lease buyouts in 2019 coming in at $1.52 million. The high price tag means strong sales revenue for the company as more hospitals explore robotics, but Intuitive also has a leasing program that allows hospitals to obtain the platform without paying the entire price upfront. This is a smart move for the company, as it can lead to more sales and recurring revenue streams as the industry continues to grow.

Pandemic Impacts

We know that Intuitive Surgical has a compelling business model and a cutting-edge product, but investors should understand that COVID-19 is hitting the company’s earnings hard. A lot of this has to do with a sharp decline in elective procedures. The company generates revenue from the sale of its instruments along with accessories used in every surgical procedure. There was a 19% year-over-year decrease in the amount of worldwide da Vinci procedures in Q2, which was a leading driver of a 22% year-over-year revenue decrease in Q2.

With that said, we should be seeing an uptick in elective procedures in the coming months as the pandemic starts to subside. Although Q2 was not a strong quarter for the company at all, its shares have risen over 12% since the earnings report was released. That tells us that the market is pricing in a sharp recovery for the company’s revenue, but keep in mind that there are some near term risks related to elective procedure volumes and financial pressures on hospitals.

The Bottom Line

This is a cutting-edge company that is completely changing the way that many surgeries are performed. It’s innovative medical technology and competitive dominance in a growing market make it worth a look for your portfolio. Keep an eye out for any significant dips if you are interested in adding shares, as the stock is likely due for a pullback soon.

Should you invest $1,000 in Intuitive Surgical right now?

Before you consider Intuitive Surgical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intuitive Surgical wasn't on the list.

While Intuitive Surgical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Intuitive Surgical (ISRG)2.1$343.59+0.6%N/A25.68Hold$335.40
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.